Rexahn names new CMO
This article was originally published in Scrip
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer, has named Dr Ely Benaim chief medical officer. In this role, Dr Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the company. Most recently Dr Benaim was senior vice-president of regulatory affairs and chief medical officer of Berg Pharma.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.